Bloomberg Intelligence

Array Deal Gives Pfizer Deep Cancer Expertise: Fazeli

Share this episode
Anyone with this link can open it.
Share Link
Start at 0:00

This episode isn’t summarized yet

Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.

Show notes

Sam Fazeli, Director of Research for Bloomberg Intelligence, on Pfizer expanding its cancer platform with the $10.6 billion Array BioPharma deal. Leland Miller, CEO of China Beige Book International, on why Xi Jinping and Trump will want to make a deal at the G20.  Matt Maley, Managing Director and Equity Strategist for Miller Tabak & Co., on why markets could see a leg down, and what to expect from Jay Powell.  Yalman Onaran, Senior Finance Writer for Bloomberg, on Deutsche Bank considering shuttering its U.S. equities trading unit. Hosted by Lisa Abramowicz and Paul Sweeney.  

See omnystudio.com/listener for privacy information.

Couldn't load the audio. A blocker may be stopping the show's tracking links. Open the file